EC rejects CHMP negative opinion on Translarna; returns for re-evaluation; 2024 guidance paused

PTC THERAPEUTICS, INC.

EC decided not to adopt CHMP's negative opinion for Translarna annual renewal; returns to CHMP for re-evaluation.
Translarna remains authorized and available in Europe; EC asks CHMP to consider real-world evidence.
PTC pauses 2024 total revenue guidance due to uncertainty from continued Translarna authorization upside.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.